Next-generation sequencing is changing how antibody discovery teams understand library performance, selection outputs and candidate diversity. Rather than relying only on small numbers of picked clones or traditional sequencing methods, NGS can provide a deeper view of how binders emerge, enrich and diversify across a discovery campaign.
In the full article, Isogenica explores how NGS can support modern antibody discovery by validating library quality, identifying rare binders and helping teams make more informed decisions during candidate selection. The blog also discusses how deeper sequence data can reduce the risk of missing valuable clones that may be masked by enrichment bias or overlooked by lower-throughput approaches.
The article connects NGS to a broader shift towards data-driven VHH discovery. High-throughput sequencing can support richer experimental datasets, improve triage and provide a stronger foundation for AI-assisted antibody engineering. For teams working with large synthetic libraries, sequence depth is not just a technical advantage — it can be central to finding the right binders faster and with greater confidence.
Read the full blog:
https://isogenica.com/ngs-in-antibody-discovery-how-deep-is-your-sequence/